Prescription dose in permanent 131Cs seed prostate implants

Medical Physics

Volumn 32, Issue 8, 2005, Pages 2496-2502

  Yue, Ning ^a   Heron, Dwight E ^a   Komanduri, Krishna ^a   Huq, M Saiful ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; TUMORS;

DOSE PRESCRIPTION; EMITTED PHOTONS; LINEAR QUADRATIC; PROSTATE CANCERS; PROSTATE IMPLANTS; RADIOBIOLOGICAL MODELING; RADIOBIOLOGICAL PARAMETERS; SEED IMPLANTS;

UROLOGY;

CESIUM; CESIUM 131; IODINE 125; PALLADIUM 103; UNCLASSIFIED DRUG;

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; EDEMA; HALF LIFE TIME; HUMAN; IMPLANT; MALE; MODEL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOBIOLOGY; TUMOR CELL; TUMOR GROWTH;

EID: 23944439367     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.1951062     Document Type: Article

References (20)

1. 125I brachytherapy," Int. J. Radiat. Oncol., Biol., Phys. 51, 31-40 (2001).
2. J. C. Blasko, P. D. Grimm, J. E. Sylvester, K. R. Badiozamani, D. Hoak, and W. Cavanagh, "Palladium-103 brachytherapy for prostate carcinoma," Int. J. Radiat. Oncol., Biol., Phys. 46, 839-850 (2000).
3. R. Nath, L. L. Anderson, G. Luxton, K. A. Weaver, J. F. Williamson, and A. S. Meigooni, "Dosimetry of interstitial brachytherapy sources: Recommendation of the AAPM radiation therapy committee task group no. 43," Med. Phys. 22, 209-234 (1995).
4. J. F. Williamson, B. M. Coursey, L. A. DeWerd, W. F. Hanson, R. Nath, and G. Ibbott, "Guidance to users of Nycorred Amersham and North American Scientific, Inc., I-125 interstitial sources: Dosimetry and calibration changes: Recommendations of the American Associate of Physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on Low-Energy Seed Dosimetry," Med. Phys. 26, 570-573 (1999).
5. 103Pd Interstitial Source Calibration and Dosimetry: Implications for dose specification and prescription," Med. Phys. 27, 643 (2000).
6. M. K. Murphy, R. K. Piper, L. R. Greenwood, M. G. Mitch, P. J. Lamperti, S. M. Seltzer, M. J. Bales, and M. H. Phillips, "Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy," Med. Phys. 31, 1529-1538 (2004).
7. C. C. Ling, "Permanent implants using Au-198, Pd-103, and I-125: Radiobiological considerations based on the linear quadratic model," Int. J. Radiat. Oncol., Biol., Phys. 23, 81-87 (1992).
8. 103Pd prostate permanent seed implants-A biomathematical model," Phys. Med. Biol. 47, 1185-1204 (2002).
9. R. G. Dale, "The application of the linear-qualratic dose-effect equation to fractionated and protracted radiotherapy," Br. J. Radiol. 58, 515-528 (1985).
10. R. G. Dale, "Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model," Br. J. Radiol. 62, 241-244 (1989).
11. J. B. Mitchell, J. S. Bedford, and S. M. Barley, "Dose-rate effects in mammalian cells in culture. III Comparison of cell killing and cell lines," Radiat. Res. 79, 537-551 (1979).
12. M. J. Rivard, B. M. Coursey, L. A. DeWerd, W. F. Hanson, M. S. Huq, G. S. Ibbott, M. G. Mitch, R. Nath, and J. F. Williamson, "Update of AAPM task group no. 43 report: A revised AAPM protocol for brachytherapy calculations," Med. Phys. 31, 633-674 (2004).
13. 103Pd prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition," Int. J. Radiat. Oncol., Biol., Phys. 41, 1069-1077 (1998).
14. J. Z. Wang, M. Cuerrero, and X. A. Li, "How low is the α/beta; ratio for prostate cancer?" Int. J. Radiat. Oncol., Biol., Phys. 55, 194-203 (2003).
15. B. R. Prestidge, W. S. Bice, E. J. Kiefer, and J. J. Prete, "Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy," Int. J. Radiat. Oncol., Biol., Phys. 40, 1111-1115 (1998).
16. G. S. Merrick, W. M. Butler, A. T. Dorsey, and H. L. Walbert, "Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy," Radiat. Oncol. Invest. 6, 182-190 (1998).
17. J. Z. Wang, X. A. Li, C. X. Yu, and S. J. DiBiase, "The low α/β ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?" Int. J. Radiat. Oncol., Biol., Phys. 57, 1101-1108 (2003).
18. H. B. Kal and M. P. R. Van Gellekom, "How low is α/β ratio for prostate cancer?" Int. J. Radiat. Oncol., Biol., Phys. 57, 1122-1130 (2003).
19. K. Haustermans and J. F. Fowler. "A comment on proliferation rates in human prostate cancer," Int. J. Radiat. Oncol., Biol., Phys. 48, 303 (2000).
20. 103Pd," Int. J. Radiat. Oncol., Biol., Phys. 47, 1165-1167 (2000).